It begins by reviewing the basic characteristics of the medications used to treat insomnia. This article provides the information required to optimize medication management of insomnia.
#Prazosin medication for insomnia how to#
Carrying out this process requires awareness of: 1) the basic characteristics of all of the insomnia medications 2) the fundamental ways that insomnia may differ among individuals that can affect the optimal choice of treatment and 3) the available data that provide guidance as to how to match insomnia medication characteristics to the nature of an individual's sleep complaint. Optimizing the medication management of insomnia for a given patient requires that the clinician select an agent which has characteristics that make it most likely to effectively and safely address the sleep difficulty experienced by that individual. A final factor that must be addressed in order to optimize pharmacotherapy of insomnia is the presence of co-morbidities such as mood disorders, anxiety disorders, pain, and substance use/dependence. Another such factor distinguishing patients is is the temporal pattern of their sleep problems across nights (nightly, intermittent and frequent, intermittent and occasional). One of the ways in which insomnia patients differ is the time of night when their sleep problems occur (problems with onset, maintenance, and/or early morning sleep difficulty). The medications available for treating insomnia also vary in their characteristics and, as a result, in their suitability for patients with the different presentations of insomnia that are encountered in practice. The nature of the sleep problem experienced by those with insomnia varies. However, this approach does a disservice to insomnia sufferers. The use of these medications is often carried out as a “one-size-fits-all” endeavor in which clinicians identify a medication that they prefer and administer it to all individuals who complain of disturbed sleep. Food and Drug Administration (FDA) for this purpose 2) agents which are approved by the FDA for the treatment of another condition but are used “off-label” for the treatment of insomnia and 3) agents that are available “over-the-counter” (OTC) for insomnia treatment. These agents include: 1) a group that are approved by the U.S. It is hoped that the treatment tailoring methods discussed herein serve as a means of improving the clinical management of insomnia and, thus, improve the lives of the many patients who suffer from this common and impairing condition.Ī number of different types of medications are currently available for the treatment of insomnia. Lastly, we discuss future directions for the optimizing pharmacologic management of insomnia. This review includes discussions that illustrate how to best choose a medication based on the characteristics of the available medications, the key differences among insomnia patients, and the available research literature. This is followed by a review of the fundamental ways that individuals with insomnia may differ and affect the choice of medication therapy. This article is intended to assist clinicians and researchers in carrying out this optimization. As a result, optimizing the medication treatment of insomnia for a given patient requires that the clinician select an agent for use which has characteristics that make it most likely to effectively and safely address the type of sleep difficulty experienced by that individual.
These agents differ in their properties, their safety and efficacy when used for different insomnia patient subtypes, and the available data on their efficacy and safety in these subtypes. Food and Drug Administration (FDA), agents approved by the FDA for another condition that are used “off-label” to treat insomnia, and agents available “over-the-counter” that are taken by individuals with insomnia. These medications include agents approved as insomnia therapies by the U.S. A number of medications are available for treating patients with insomnia.
0 kommentar(er)
